In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents - Test2 - elhamkhani - TriplyDB

In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents

In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents

http://www.wikidata.org/entity/Q28379204

about

The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria Determining Linezolid's baseline in vitro activity in Canada using gram-positive clinical isolates collected prior to its national release.Resistance to linezolid caused by modifications at its binding site on the ribosome Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model Clinical experience with linezolid in the treatment of resistant gram-positive infections Novel bacterial metabolite merochlorin A demonstrates in vitro activity against multi-drug resistant methicillin-resistant Staphylococcus aureus Hematologic effects of linezolid: summary of clinical experience.Population pharmacokinetics and pharmacodynamics of linezolid-induced thrombocytopenia in hospitalized patients.In vitro and in vivo synergistic activities of linezolid combined with subinhibitory concentrations of imipenem against methicillin-resistant Staphylococcus aureus Identification, cloning, and functional characterization of EmrD-3, a putative multidrug efflux pump of the major facilitator superfamily from Vibrio cholerae O395 Polyphyletic emergence of linezolid-resistant staphylococci in the United States Genetics and pulmonary medicine. 5. Genetics of drug resistant tuberculosis Pharmacokinetics and safety of recently approved drugs used to treat methicillin-resistant Staphylococcus aureus infections in infants, children and adults.Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, an Antibiotic resistance: a current perspective.Oxazolidinone resistance mutations in 23S rRNA of Escherichia coli reveal the central region of domain V as the primary site of drug action.Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens Penetration of linezolid into soft tissues of healthy volunteers after single and multiple doses.Linezolid activity compared to those of selected macrolides and other agents against aerobic and anaerobic pathogens isolated from soft tissue bite infections in humans.In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci MICs of oxazolidinones for Rhodococcus equi strains isolated from humans and animals.Comparative in vitro activities of linezolid, quinupristin-dalfopristin, moxifloxacin, and trovafloxacin against erythromycin-susceptible and -resistant streptococci.Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections.In vitro activities of linezolid, meropenem, and quinupristin-dalfopristin against group C and G streptococci, including vancomycin-tolerant isolates Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci.In vitro activity of PNU-100766 (linezolid), a new oxazolidinone antimicrobial, against Nocardia brasiliensis.Intrapulmonary pharmacokinetics of linezolid Activities of new fluoroquinolones, ketolides, and other antimicrobials against blood culture isolates of viridans group streptococci from across Canada, 2000.Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in Canada during 2000.In vitro activity of linezolid against key gram-positive organisms isolated in the united states: results of the LEADER 2004 surveillance program.Concentrations in plasma, urinary excretion, and bactericidal activity of linezolid (600 milligrams) versus those of ciprofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose In vivo efficacy of continuous infusion versus intermittent dosing of linezolid compared to vancomycin in a methicillin-resistant Staphylococcus aureus rabbit endocarditis model.Structural insights into species-specific features of the ribosome from the pathogen Staphylococcus aureus.Skin and soft tissue concentrations of tedizolid (formerly torezolid), a novel oxazolidinone, following a single oral dose in healthy volunteers Linezolid for treatment of chronic extensively drug-resistant tuberculosis.In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs Pharmacokinetics and efficacy of linezolid in a gerbil model of Streptococcus pneumoniae-induced acute otitis media.Linezolid pharmacokinetics in adult patients with cystic fibrosis Worldwide assessment of linezolid's clinical safety and tolerability: comparator-controlled phase III studies In vitro activities of linezolid combined with other antimicrobial agents against Staphylococci, Enterococci, Pneumococci, and selected gram-negative organisms.

P2860

Q24519053-ECB833B4-A174-48F8-9445-DEC048949AD5 Q24535971-4D0A946C-BAE3-4B4C-AE0F-53AA948BE4FD Q27006772-1784DDB5-CAE3-4CFA-A70C-CB3B597C1A3B Q28343296-C882D7A3-06A1-4760-BDC0-48891754AE8E Q28363047-A6D5ADE5-228E-4AF3-98AB-3C8C85AC671F Q28478951-63A3A451-DF37-49DE-A5DA-D7F02023729E Q33343252-9EAB01B6-57AC-442B-B71B-31BC3610793E Q33439246-36747CD3-EF0E-4AE8-AC0B-00F11CDDBF1C Q33556476-3C9245A2-CEC2-4CDF-B30D-E90A1F26C930 Q33603996-40346CA1-A6C9-41AA-AD0F-36B6B0D9E7E0 Q33613747-3D5F1126-8F04-4C83-8AC6-5843C5E9B185 Q33630442-EE929535-C853-4D82-936C-DBC6923D5FCC Q33657212-FB947DE6-E3C7-4137-9080-DAC06E9EA38A Q33691841-D1EFEB10-EF1A-439F-8A48-78B2A300F996 Q33693954-E0EF2402-B8FE-4B60-A772-BB2B4E9C3201 Q33787419-6A9FF728-A9C3-480D-9125-F177D9A3D6BE Q33788308-1E102865-A1BD-4BE8-AEC7-89005B5B4412 Q33836578-75881EBD-83F3-4406-AE12-ABD6CDF83813 Q33976974-F838FAFC-3C60-49CA-B1F0-CCE84CBD53C1 Q33977497-B0A3B909-1412-4D39-9386-936CD064566F Q33979553-A8A77AAD-DD21-44A8-9891-9606D92465B9 Q33979988-152DC023-2D10-4081-BD5A-A67F9F325F01 Q33981016-A5205237-6A63-4E28-903F-737AA62E2F35 Q33982480-51E4B4BF-0686-480E-82C8-1DB5B962E137 Q33982606-797A8B28-1BBC-40E9-84C0-D52111FCFD7F Q33983749-CA7DBB00-1BA1-448F-BF0C-DF41AE7F6D07 Q34106719-24A3D4D7-073E-457B-B8FF-C21B991F4116 Q34107331-E59D32F0-6F80-4F2F-A075-70251A186B91 Q34107785-577CEF06-81FE-45AF-83D4-57E4280EADAC Q34228269-ED86B451-6C7B-402E-9FC6-B7BE6D6DE5A1 Q34230275-7726CA60-C318-457F-A70B-F1A399D1731F Q34252432-066C2FBB-BFD8-4557-A1B1-A4E6723A5DAE Q34497915-24289B88-ED47-4B44-95AA-C8A540F62954 Q34638260-AB132456-B8AC-4A3C-A89D-4AF8512B6D4E Q34644127-BE9A021B-C3EB-41FD-B3F2-2EBD8747E72B Q34722433-9258C9D5-9389-4A2D-9D7F-3AA11B9D557A Q34883537-5C19BA54-C369-466E-BDA9-2AB992D71A6C Q35006010-0582CB17-AA92-4D6A-B932-6AB0C93F9478 Q35013856-E8F1EE2B-0F94-4BD0-AF6B-DCD4BE27F2EA Q35014416-76D2E831-245F-4343-A35D-50C04C815289

P2860

In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents

http://www.wikidata.org/entity/Q28379204

description

1996 nî lūn-bûn

@nan

1996 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

1996 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

1996年の論文

@ja

1996年論文

@yue

1996年論文

@zh-hant

1996年論文

@zh-hk

1996年論文

@zh-mo

1996年論文

@zh-tw

1996年论文

@wuu

name

In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents

@ast

In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents

@en

In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents

@nl

type

label

In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents

@ast

In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents

@en

In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents

@nl

prefLabel

In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents

@ast

In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents

@en

In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents

@nl

P1433

Q28379204-B4DE4B6D-E403-4AD9-A4A6-08EFD5673F8E

P1476

Q28379204-2132058E-47FF-417B-B034-155E520C14CF

P2093

Q28379204-34FDF4D7-52D4-4B05-AE23-BC4DEC275A1A

Q28379204-545437C8-35C2-4521-BDEC-DF03584914C8

Q28379204-54AF4D1B-9FD0-420E-87E7-762E1242E42C

Q28379204-73FAA9C3-FCB5-427A-8B55-6F19E92C2D3F

Q28379204-8BDE2CA3-7B9D-436F-9FA9-3C976900C766

Q28379204-9FE3D6F5-B51E-425E-8C80-89CDEC35D872

Q28379204-C932DE4A-7433-43F2-A246-40DB91A8D3CF

Q28379204-CCE31BF8-3AA7-4018-AC10-F5B90E25D305

Q28379204-DE09A67B-ACEE-46E8-8450-AE6C511E2B75

P2860

Q28379204-01E5B02D-BFD5-4EA4-BACF-25C00EE0364D

Q28379204-05EC273C-35F7-4FF2-9A82-ABB40350CC52

Q28379204-2BCC1795-CD0F-49E4-B958-8C0E4A1D803C

Q28379204-58C73166-BA0D-4BC4-88A7-18838B069889

Q28379204-5C1ADC61-A2B0-4A4D-B89A-6E99FC064C20

Q28379204-7DF74E42-DFC0-47BE-B728-92ABFAEFFA01

Q28379204-973A1700-5702-477A-875A-C5808B884541

Q28379204-B102C5A2-E9EF-4453-92E3-76B40B1D90C6

Q28379204-B7352DED-70BD-47A9-9F06-5A68597D9AD0

Q28379204-CB87B09D-2196-4A39-A02E-15C12E47CFDE

P304

Q28379204-0A4E12BB-3C46-4378-93E1-A75DAFFF36AA

P31

Q28379204-75169C51-CDD6-4DE3-ACF5-BBCCD2C3A6DE

P3181

Q28379204-DD67329E-32F1-4640-8151-00AC42D599AF

P356

Q28379204-1BDE2E53-2B84-4306-A1F1-C1AB7C8917E5

P407

Q28379204-091D7875-A500-4C7D-A22E-15862CD93287

P433

Q28379204-CB15650A-8C1E-49D3-82A9-6319AEF89E30

P478

Q28379204-5A851F5F-56EC-4DC9-BBF2-DDC0FE8BA4E6

P577

Q28379204-F489DFEA-29EE-45B8-952C-13BB1B00A83A

P698

Q28379204-2B86CE78-80FD-45AA-9D18-8C421063CB05

P932

Q28379204-BEF38125-19F6-47CA-AA28-12901A89C980

P3181

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents

@en

P2093

Allison JW

http://www.w3.org/2001/XMLSchema#string

Barbachyn MR

http://www.w3.org/2001/XMLSchema#string

Brickner SJ

http://www.w3.org/2001/XMLSchema#string

Glickman SE

http://www.w3.org/2001/XMLSchema#string

Hutchinson DK

http://www.w3.org/2001/XMLSchema#string

Kilburn JO

http://www.w3.org/2001/XMLSchema#string

Schaadt RD

http://www.w3.org/2001/XMLSchema#string

Yagi BH

http://www.w3.org/2001/XMLSchema#string

Zurenko GE

http://www.w3.org/2001/XMLSchema#string

P2860

Oxazolidinones, a new class of synthetic antibacterial agents: in vitro and in vivo activities of DuP 105 and DuP 721

Oxazolidinones, a new class of synthetic antituberculosis agent. In vitro and in vivo activities of DuP-721 against Mycobacterium tuberculosis

The mechanism of action of DuP 721, a new antibacterial agent: effects on macromolecular synthesis

Comparative in vitro activity of the new oxazolidinones DuP 721 and DuP 105 against staphylococci and streptococci

In vitro evaluation of DuP 105 and DuP 721, two new oxazolidinone antimicrobial agents.

Mechanism of action of DuP 721: inhibition of an early event during initiation of protein synthesis.

Bactericidal activity of deptomycin (LY146032) compared with those of ciprofloxacin, vancomycin, and ampicillin against enterococci as determined by kill-kinetic studies

In vitro activities of two oxazolidinone antimicrobial agents, DuP 721 and DuP 105.

Mechanism of action and in vitro and in vivo activities of S-6123, a new oxazolidinone compound

Defective killing of enterococci: a common property of antimicrobial agents acting on the cell wall.

P304

839-845

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1621670

http://www.w3.org/2001/XMLSchema#string

P356

10.1128/AAC.40.4.839

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

40

http://www.w3.org/2001/XMLSchema#string

P577

1996-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

8849237

http://www.w3.org/2001/XMLSchema#string

P932

163216

http://www.w3.org/2001/XMLSchema#string